#ESMO26：双特异性 EGFR/HER3 ADC iza-bren 在既往接受过治疗的 HR+/HER2− 晚期乳腺癌患者中，使疾病进展或死亡风险较化疗降低 59%。OS 数据尚不成熟。
#BreastCancer #ADC #Oncology
36 浏览 · 0 赞 · 0 转发 · 1 回复
Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgTroFuse-021/ENGOT-ov85/GOG-3102: Phase 3 study of maintenance sacituzumab tirumotecan (Sac-TMT) with or without bevacizumab versus standard of care in patients with advanced ovarian cancer
https://esmocongress.esmo.orgNeoadjuvant sacituzumab govitecan plus pembrolizumab in resectable non-small cell lung cancer: Phase II CITADEL study
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.org- MedShr@medshronline
Response rates, early safety signals and the sequencing question with T-DXd and sacituzumab govitecan: full results in the MedShr ESMO 2026 Hub. 👇 https://medshr.it/23346643
来源：MedShr · x.com